.png){kind=icon}
.png){kind=icon}
Return
Synchronous Late-Onset of Limbic Encephalitis and Tumefactive Demyelinating Lesion After the End of Immunotherapy
.png){kind=icon}
OA
AI
B
S
B
S
DOI：10.1097/RLU.0000000000006535.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Immunoreactive encephalitis is a very rare side effect of immunotherapy, which can lead to severe morbidity. Following azetolizumab, it typically occurs within 0–12 months, with a median of 15 days. In this case, immunoreactive encephalitis occurred 3.5 months after treatment with azetolizumab ended and 15.5 months after it began. Tumefactive demyelinating lesions represent a focal cerebral lesion with inflammatory demyelination. They are usually associated with multiple sclerosis, but can also occur drug-induced or in the context of autoantibody-mediated diseases. In MRI, tumefactive demyelinating lesions mimic cerebral metastases. 18F-FDG PET/CT can enhance the diagnostic precision of both immunoreactive encephalitis and tumefactive demyelinating lesions.
Keywords:
lung cancer
immunotherapy
encephalitis
late-onset
azetolizumab
Journal
IF:
9.6
Papers:
1.1W
Citations:
6.9K
Organization
No organization information available
Cited Papers